“…224) [575], transpentacin derivatives [576], bis spirocyclopentenes [577], nardoaristolone B and analogs [578], cyclaradine [579], carbocyclic nucleoside analogs [580], cyclopentenefused nucleosides [581], cyclopentenols for the preparation of enantio enriched 4-hydroxy-2-cyclopentenones [582], and failure to form a five-membered ring bridge of a nucleoside derivative by RCM [583]; (2) cyclopentenes and dihydrofurans [584]; (3) α,β-unsaturated cyclopentenones [585], including those employed in syntheses of TEI-9826 [586]; (4) five-and six-membered ring alkenes substituted by electron-withdrawing groups [587]; (5) five-and six-membered rings fused (spiro or regular fusion) to indole systems [588]; (6) fiveand six-membered rings spiro fused to a 1,2-diphenylpyrazolidine-3,5-dione ring system [589]; (7) five-to seven-membered ring carbocycles and oxygen heterocycles using biocatalytically-derived starting materials [590]; (8) five-to seven-membered ring carbocycles [591]; (9) five-to seven-membered ring carbocyclic and heterocyclic vinylboronates (e.g. 225) [592]; (10) cyclohexenes, including those employed in syntheses of fluorinated inositol analogs [593], fluorinated cyclohexenes [594], lundurine B (the enol ether was converted to the ketone without isolation) (e.g.…”